Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Clinicopathologic features and prognostic factors of breast cancer brain metastases patients based on molecular subtypes: A real-world retrospective analysis.

Shidi Zhao, Shujuan He, Danfeng Dong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13077

e13077 Background: The incidence of breast cancer brain metastases (BCBM) is increasing. Molecular subtypes of breast canc...

Associations between mindfulness, psychological distress, and coping among hematopoietic stem cell transplant caregivers.

Brooke Bethune, Marilyn Horta, Halle Smith et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18567

e18567 Background: Caregivers of allogeneic hematopoietic stem cell transplantation (HCT) patients experience significant...

Point-of-care cancer screening using saliva transmission spectroscopy and machine learning.

Huizi Chen, Ann Maguire, Janet Retseck et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22526

e22526 Background: Tier-1 cancer screening would benefit from point-of-care (POC) testing that is rapid, inexpensive, and...

Impact of social marginalization on stage at presentation and survival for invasive lobular versus ductal breast carcinoma.

David Wai Lim, Kelly A. Metcalfe, Vasily Giannakeas et al. Jun 01, 2026 pp. 641-641 10.1200/jco.2026.44.16_suppl.641

641 Background: We aim to determine how indices of social marginalization impact stage at diagnosis, health services use,...

Natural language processing (NLP) to identify neoplastic fever in the electronic medical record (EMR).

Martin Juarez-Alvarado, Luke B. Davis, Clara Becker et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13679

e13679 Background: Neoplastic fever (also known as “tumor fever”; TF), is a rare but challenging condition that can be dif...

Symptom-based individual risk prediction for late mortality: A report from the Childhood Cancer Survivor Study study (CCSS).

Elyse Zhang, Yan Chen, Jaesung Choi et al. Jun 01, 2026 pp. 10050-10050 10.1200/jco.2026.44.16_suppl.10050

10050 Background: Survivors of childhood cancer face a higher risk of late mortality than the general population. Yet no p...

Final results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated biliary tract cancer (NAPOLI-2).

Benjamin Adam Weinberg, Benjamin R. Tan, Aiwu Ruth He et al. Jun 01, 2026 pp. 4122-4122 10.1200/jco.2026.44.16_suppl.4122

4122 Background: BTCs are rare and aggressive malignancies. The first-line standard of care regimen for advanced BTC (aBTC...

Antibody-encapsulated actinomycin D for targeted cancer treatments.

C. J. Yu, Linrong Li, Lesile Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13019

e13019 Background: HER2 is overexpressed in 15-20% of breast cancers and other cancers, and HER2-targeted therapies have r...

Prevention of paclitaxel-induced neurotoxicity with lithium: Results from a multicenter, randomized, double-blind, placebo-controlled phase 2 trial (PREPARE).

Wolfgang Boehmerle, Jens U. Blohmer, Verena Imke Isabel Kiver et al. Jun 01, 2026 pp. 12129-12129 10.1200/jco.2026.44.16_suppl.12129

12129 Background: Chemotherapy-induced neurotoxicity is a frequent adverse effect of paclitaxel (PTX). It reduces quality...

Prognostic value of an MRI-derived recurrence assay in women with hormone receptor–positive, HER2-negative breast cancer: A retrospective, multi-center analysis.

Matthew P. Goetz, Qinmei Xu, Vincent Reid et al. Jun 01, 2026 pp. 560-560 10.1200/jco.2026.44.16_suppl.560

560 Background: Patients (pts) with early stage hormone receptor-positive, human epidermal growth factor receptor 2-negati...

Associations between chronic pain, depression, and social vulnerability in US adults with colon cancer.

Aimee Pehrson, Omar Ramos, Andrew Russ Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15698

e15698 Background: Chronic pain is a frequent and disabling sequela of colon cancer treatment, yet nationally representati...

Does resection of cavity shave margins impact survival in breast cancer patients?

Anees B. Chagpar, Kristalyn K. Gallagher, Carlos Garcia-Cantu et al. Jun 01, 2026 pp. 513-513 10.1200/jco.2026.44.16_suppl.513

513 Background: Randomized controlled trials have shown that resection of cavity shave margins (CSM) halves the margin pos...

Age-related immune toxicity and treatment outcomes in triple-negative breast cancer treated with pembrolizumab.

Grace Gorecki, Oyepeju Folashade Abioye, Bana Antonios et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12710

e12710 Background: Tolerability and treatment completion of pembrolizumab added to neoadjuvant chemotherapy for triple-neg...

Timing of central nervous system metastases occurrence in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: A single institution real-world analysis.

Martina Matec, Marija Križić, Marina Popovic et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13068

e13068 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are standard first-line treatment for patients with ho...

Real-world outcomes of bruton tyrosine kinase inhibitors versus venetoclax in chronic lymphocytic leukemia.

Lay She Ng, Wern Lynn NG, Yone Phar Lin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18616

e18616 Background: Bruton tyrosine kinase inhibitors (BTKi) and venetoclax-based regimens have transformed the frontline m...

KANDLELIT-014: A phase 2 study of MK-1084 as monotherapy and in combination with cetuximab in <i>KRAS</i> G12C-mutant advanced solid tumors.

Nehal J. Lakhani, Changhoon Yoo, Cornelia Schuster et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps3185

TPS3185 Background: KRAS is one of the most frequently mutated oncogenes in human cancers, with the G1...

Impact of first-line comprehensive genomic profiling on survival outcomes for patients with advanced solid tumors who received molecularly-matched therapies: 3-year follow-up of the prospective FIRST-Dx study.

Sadakatsu Ikeda, Junichi Matsubara, Kumi Mukai et al. Jun 01, 2026 pp. 3134-3134 10.1200/jco.2026.44.16_suppl.3134

3134 Background: Comprehensive genomic profiling (CGP) by next-generation sequencing has been reimbursed in Japan since 20...

Institutional disparities in actionable mutation detection in pancreatic ductal adenocarcinoma: An AACR Project GENIE analysis.

Emmanuel Omole, Kevin Han, Olamide Asifat Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16378

e16378 Background: The identification of actionable mutations in pancreatic ductal adenocarcinoma (PDAC) informs eligibili...

Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer.

Giorgio Caturegli, Ebony Jernigan, Maureen Canavan et al. Jun 01, 2026 pp. 8054-8054 10.1200/jco.2026.44.16_suppl.8054

8054 Background: The role of immunotherapy in non-metastatic EGFR-and ALK-mutated lung cancer is limited, in part because...

Efficacy and safety of tislelizumab as neoadjuvant therapy combined with MRD monitoring in locally advanced dMMR/MSI-H colon cancer: A prospective pilot study.

Miaoqing Wu, Rong-Xin Zhang, Xiaojun Wu et al. Jun 01, 2026 pp. 3651-3651 10.1200/jco.2026.44.16_suppl.3651

3651 Background: PD-1 blockade has demonstrated high efficacy in metastatic and neoadjuvant settings for dMMR/MSI-H colore...

Factors contributing to non-initiation of planned systemic therapy among inpatients evaluated for a phase II randomized controlled oncology trial.

Kolton Kardokus, Cameron Anzel, Momina Anwar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23353

e23353 Background: The Spine Patient Optimal Radiosurgery Treatment for Symptomatic MEtastatic Neoplasms (SPORTSMEN) multi...

Retrospective evaluation of immune checkpoint inhibitors in soft tissue sarcoma.

Alanna Siegenthaler, Stephanie Niforatos, Deevyashali Parekh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23570

e23570 Background: Soft tissue sarcomas (STS) are rare, and metastatic disease confers a poor prognosis. There are limited...

Cancer care experiences among sexual and gender minority adults: A qualitative descriptive study.

Jamil Abou Issa, Bonnie Jerome-D'Emilia, Alison Greidinger Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13731

e13731 Background: Sexual and gender minority (SGM) individuals experience disparities across cancer screening, treatment,...

Patterns of artificial intelligence use among physicians in Mexico: Implications for oncology practice.

Jeffrey Barragán Ortega, Eduardo Gutierrez Leon, Andrea Hinojosa-Azaola et al. Jun 01, 2026 pp. 9002-9002 10.1200/jco.2026.44.16_suppl.9002

9002 Background: Artificial intelligence (AI) is increasingly incorporated into medical practice; however, physician-level...

Temporal trends in mortality involving esophageal cancer with comorbid psychoactive substance-induced mood disorders among adults aged ≥55 years in the United States, 1999–2023: A retrospective CDC WONDER analysis.

Mahnoor Jan, Zain Ali, Taha Bin Nayyar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16049

e16049 Background: Esophageal Cancer (EC) has strong association with mental and behavioral disorders caused by psychoacti...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page